Clinical oncology pioneer joins PharmEnable’s board

Exciting news at PharmEnable: we are proud to welcome Dr Ian Collins to our board as a new non-executive director. With three decades of experience in drug discovery and drug development, Ian will support our mission to push the boundaries of what is possible in the small molecules field.

Ian Collins Non Executive Director at PharmEnable Therapeutics

“I am thrilled to join PharmEnable at such an exciting time. Their AI-enabled chemSEEK technology is a game changer, unlocking previously inaccessible targets such as those behind the blood-brain barrier or inside the cell. I am looking forward to working with PharmEnable’s board and leadership team.”

 

– Dr Ian Collins, Non-Executive Director at PharmEnable Therapeutics

Hannah Sore CEO and Co-Founder at PharmEnable Therapeutics

“All of us at PharmEnable are thrilled to welcome Ian on our journey. He brings a wealth of expertise in delivering leads and candidates in oncology and CNS disease. Together, we are developing a pipeline of innovative small molecules that can make a difference to those battling cancer and neurological conditions”

 

– Dr. Hannah Sore – CEO and Co-Founder at PharmEnable Therapeutics

Following a PhD at Cambridge University, Ian began his early medicinal chemistry career at The Neuroscience Research Centre of Merck Sharp & Dohme Ltd. He then moved to establish a team at The Institute of Cancer Research, London, becoming Professor of Medicinal Chemistry and Head of Chemistry. Ian was a scientific co-founder of the protein degrader company Monte Rosa Therapeutics Inc. Since 2022, he has served as an independent scientific advisor.

Join us in extending a warm welcome to Ian.